Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
|
|
Xencor Inc (XNCR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Investor presentation, Quarterly results |
| 08/03/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/23/2022 |
8-K
| Quarterly results |
| 11/08/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 02/23/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/04/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 02/24/2020 |
8-K
| Quarterly results |
| 11/05/2019 |
8-K
| Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 02/25/2019 |
8-K
| Quarterly results |
| 11/05/2018 |
8-K
| Quarterly results |
| 08/06/2018 |
8-K
| Quarterly results |
| 05/07/2018 |
8-K
| Quarterly results |
| 02/27/2018 |
8-K
| Quarterly results |
| 11/07/2017 |
8-K
| Quarterly results |
| 08/07/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 02/28/2017 |
8-K
| Form 8-K - Current report |
| 11/02/2016 |
8-K
| Quarterly results|
Docs:
|
"Xencor Reports Third Quarter 2016 Financial Results MONROVIA, Calif., — November 2, 2016 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the third quarter ended September 30, 2016 and provided a review of pipeline and corporate highlights. “During the third quarter, we initiated clinical trials across our internal pipeline of XmAb programs, including Phase 1studies of subcutaneously administered XmAb®5871 and XmAb®7195, and a first-in-human Phase 1study of our lead immuno-oncology bispecific antibody candidate, XmAb®14045,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “With these miles..." |
|
| 08/02/2016 |
8-K
| Form 8-K - Current report |
| 05/02/2016 |
8-K
| Quarterly results|
Docs:
|
"Xencor Reports First Quarter 2016 Financial Results Monrovia, CA — May 2, 2016 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first quarter ended March 31, 2016 and provided a review of pipeline and corporate highlights. “During the quarter we initiated Phase 2 trials with XmAb®5871 in both IgG4-Related Disease and systemic lupus erythematosus , two diseases with high unmet need and a strong rationale for B-cell inhibition,” said Bassil Dahiyat, Ph.D., President and Chief Executive Officer of Xencor. “We also continued to advance our broad pipeline of wholly-owned and partnered programs. We remain on track to re..." |
|
| 03/07/2016 |
8-K
| Form 8-K - Current report |
| 11/03/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Xencor Reports Second Quarter 2015 Financial and Operating Results MONROVIA, Calif. — August 4, 2015 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2015 and provided a review of its business highlights. “Currently eight XmAb® antibody candidates are in clinical testing, six with partners and two internal. The accelerating momentum of this pipeline of antibodies is a direct result of the breadth of immune biology that our proprietary XmAb platform addresses. We recently unveiled updates on our development plans for our internally-led programs XmAb®5871 in the rare autoimmune disorde...",
"Q2 2015 Xencor, Inc. Earnings Conference Call Transcript" |
|
| 05/04/2015 |
8-K
| Quarterly results|
Docs:
|
"Xencor Reports First Quarter 2015 Financial and Operating Results Monrovia, Calif. — May 4, 2015 — Xencor Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2015 and provided a review of business highlights. “Following our equity offering in February, which raised net proceeds of approximately $115 million, we are in a strong financial position to advance our lead pipeline programs and maximize the potential of our XmAb technology,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “We started 2015 with two important data readouts which included top-line interim data f..." |
|
|
|
|